74 related articles for article (PubMed ID: 19941009)
1. Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma.
Tanaka S; Arii S
J Hepatobiliary Pancreat Sci; 2010 Jul; 17(4):413-9. PubMed ID: 19941009
[TBL] [Abstract][Full Text] [Related]
2. Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue.
Yasen M; Mizushima H; Mogushi K; Obulhasim G; Miyaguchi K; Inoue K; Nakahara I; Ohta T; Aihara A; Tanaka S; Arii S; Tanaka H
Cancer Sci; 2009 Mar; 100(3):472-80. PubMed ID: 19134008
[TBL] [Abstract][Full Text] [Related]
3. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
4. Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.
Liu F; Wang G; Wang X; Che Z; Dong W; Guo X; Wang Z; Chen P; Hou D; Zhang Q; Zhang W; Pan Y; Yang D; Liu H
Oncotarget; 2017 Apr; 8(17):27953-27965. PubMed ID: 28427193
[TBL] [Abstract][Full Text] [Related]
5. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.
Nakao K; Tanaka S; Miura T; Sato K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
Cancer Sci; 2015 Aug; 106(8):1016-22. PubMed ID: 26011703
[TBL] [Abstract][Full Text] [Related]
6. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy.
Tanaka S; Arii S; Yasen M; Mogushi K; Su NT; Zhao C; Imoto I; Eishi Y; Inazawa J; Miki Y; Tanaka H
Br J Surg; 2008 May; 95(5):611-9. PubMed ID: 18311747
[TBL] [Abstract][Full Text] [Related]
7. Overexpression and amplification of Aurora-A in hepatocellular carcinoma.
Jeng YM; Peng SY; Lin CY; Hsu HC
Clin Cancer Res; 2004 Mar; 10(6):2065-71. PubMed ID: 15041727
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-cancer substance, MK615, from ume, a variety of Japanese apricot, inhibits growth of hepatocellular carcinoma cells by suppressing Aurora A kinase activity.
Okada T; Sawada T; Osawa T; Adachi M; Kubota K
Hepatogastroenterology; 2007 Sep; 54(78):1770-4. PubMed ID: 18019715
[TBL] [Abstract][Full Text] [Related]
10. Aurora B kinase expression in ependymal neoplasms.
Gibson SE; Zeng WF; Weil RJ; Prayson RA
Appl Immunohistochem Mol Morphol; 2008 May; 16(3):274-8. PubMed ID: 18301241
[TBL] [Abstract][Full Text] [Related]
11. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Fraedrich K; Schrader J; Ittrich H; Keller G; Gontarewicz A; Matzat V; Kromminga A; Pace A; Moll J; Bläker M; Lohse AW; Hörsch D; Brümmendorf TH; Benten D
Clin Cancer Res; 2012 Sep; 18(17):4621-32. PubMed ID: 22753592
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of activated Cdc42-associated kinase1 (Ack1) predicts tumor recurrence and poor survival in human hepatocellular carcinoma.
Wang B; Xu T; Liu J; Zang S; Gao L; Huang A
Pathol Res Pract; 2014 Dec; 210(12):787-92. PubMed ID: 25445114
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study.
Tanaka S; Mogushi K; Yasen M; Ban D; Noguchi N; Irie T; Kudo A; Nakamura N; Tanaka H; Yamamoto M; Kokudo N; Takayama T; Kawasaki S; Sakamoto M; Arii S
Hepatology; 2011 Oct; 54(4):1273-81. PubMed ID: 22006857
[TBL] [Abstract][Full Text] [Related]
14. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
Ching YP; Leong VY; Lee MF; Xu HT; Jin DY; Ng IO
Cancer Res; 2007 Apr; 67(8):3601-8. PubMed ID: 17440071
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
[No Abstract] [Full Text] [Related]
16. Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP as a transforming target of Aurora-A.
Yu CT; Hsu JM; Lee YC; Tsou AP; Chou CK; Huang CY
Mol Cell Biol; 2005 Jul; 25(14):5789-800. PubMed ID: 15987997
[TBL] [Abstract][Full Text] [Related]
17. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.
Wang C; Jin G; Jin H; Wang N; Luo Q; Zhang Y; Gao D; Jiang K; Gu D; Shen Q; Huo X; Hu F; Ge T; Zhao F; Chu W; Shu H; Yao M; Cong W; Qin W
Oncotarget; 2015 Feb; 6(5):2903-16. PubMed ID: 25609201
[TBL] [Abstract][Full Text] [Related]
18. Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.
Warner SL; Munoz RM; Stafford P; Koller E; Hurley LH; Von Hoff DD; Han H
Mol Cancer Ther; 2006 Oct; 5(10):2450-8. PubMed ID: 17041088
[TBL] [Abstract][Full Text] [Related]
19. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
20. Advanced HCC: emerging molecular therapies.
Finn RS
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):25-34. PubMed ID: 22419002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
